Indeed, CXCR4 blockade significantly reduced chemotaxis of pro‐tumorigenic macrophages in oral squamous cell carcinoma[67] and several CXCR4 antagonists, as well as of CCR2 and CSF1R, are currently in clinical trials.[68] Nevertheless, targeting of PYK2 alone might not be sufficient for cancer therapy, whereas combining PYK2 targeting with other therapeutic agents could be beneficial for subsets of breast cancer patients. The gene discussed is CXCR4; the disease is breast cancer.